€0.002
Your prediction
Melodiol Global Health Ltd. Stock
Pros and Cons of Melodiol Global Health Ltd. in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Creso Pharma Ltd., an emerging player in the industry, appears to have experienced some financial challenges in recent years. The company's financials showcase a negative trend in net income and cash flows. Despite these issues, Creso Pharma Ltd. still maintains a stable asset base and shows the ability to raise funds through equity in the capital markets. A thorough analysis of the company's financial health reveals several pros and cons that investors should take into account.
*Pros: *
Stable Asset Base: Creso Pharma Ltd. has shown a consistent growth in its total assets over the past three years, increasing from AUD 19.1 million in 2020 to almost AUD 37.9 million in 2022. This consists of both current and non-current assets, signifying a stable and diverse asset base.